From the Society of Nuclear Medicine meeting exhibit floor, an audio interview with Karthik Kuppusamy, Ph.D., general manger for Americas nuclear medicine, PET/CT, and cyclotron business at GE Healthcare, who touted the company’s Discovery VCT.
At this year's Society of Nuclear Medicine meeting, cardiac PET is emerging from the long shadow of PET/CT for oncology applications. Rejuvenated by increased Medicare reimbursements for perfusion that began this year, PET is also reaping the benefits of a growing body of research supporting its use.
On the SNM exhibit floor, Karthik Kuppusamy, Ph.D., general manger for Americas nuclear medicine, PET/CT, and cyclotron business at GE Healthcare, touted the company's Discovery VCT. The device combines 64-slice CT and high resolution PET as a one-stop shop for assessment of suspected cardiovascular disease. Discovery VCT delivers analyses of ventricular function, wall motion, and perfusion, as well as coronary CT angiograms and calcium scoring, in less than 30 minutes.
But rest and stress imaging using the Discovery VCT to identify perfusion defects presents special challenges that require the deft use of CT during pharmaceutical stress - and a special algorithm developed by GE.